Drug Resistance Clinical Trial
— BenziROfficial title:
Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon
Verified date | July 2021 |
Source | Centre de Recherche Médicale de Lambaréné |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Soil-transmitted helminths (STHs) infections are common in subtropics and mostly affect the poorest communities, with an impact on human health in many parts of the world. In 2017, World Health organization (WHO) reports more than 1.5 billion people are infected with soil-transmitted helminths worldwide, including 568 million school-age children who need treatment and preventive interventions. Preventive chemotherapy and periodic mass administration with benzimidazoles (BZ) [albendazole (ABZ) and mebendazole (MBZ)] are used to control these parasites. However, rapid reinfection with Ascaris lumbricoides within six months after a completed treatment has been reported, while the reinfection with hookworms is slow. Similarly, the efficacy of these drugs on Trichuris trichiura cure rate is poor. After many years of use of this drug class, there is an increase possibility that BZ resistance could develop. This resistance may occur due to single nucleotide polymorphisms (SNPs) in the β-tubulin gene at positions 167, 198 or 200, as has been reported in animals. Little data exist to show whether any of these polymorphisms do influence the BZ efficacy against STH in humans. The present study will develop methods to look for molecular evidence of BZ drug resistance in human population in order to support the investigation of the control and elimination of neglected tropical diseases (NTDs) in our communities.
Status | Completed |
Enrollment | 255 |
Est. completion date | January 30, 2021 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 2 Years to 17 Years |
Eligibility | Inclusion Criteria: - Living in Lambaréné and surrounding areas - Written informed consent or assent - Microscopy positive for any major Soil-Transmitted helminths Exclusion Criteria: - Microscopy negative for any STH - Pregnant women - Do not be available for followed up. |
Country | Name | City | State |
---|---|---|---|
Gabon | Centre de Recherches Médicales de Lammbaréné | Lambaréné | Moyen- Ogooué |
Lead Sponsor | Collaborator |
---|---|
Centre de Recherche Médicale de Lambaréné |
Gabon,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of eggs rate reduction . | The assessment of efficacy will be the level of the eggs rate reduction . The assessment will be done at weeks 3 and 6 and a different treatment regimen will be compared according to protocol and intention to treat.
This evaluation will be based on the same parasitological examinations carried out at the beginning. Using polymerase chain reaction(PCR) for a better, appreciation of the efficacy of Benzimidazole. |
three weeks to six weeks | |
Primary | Assessment of cure rate | The assessment of efficacy as a cure rate, based on the absence of eggs at three and six weeks post treatment, using microscopy and PRC examination. | three weeks to six weeks | |
Secondary | The assessment of safety | The adverse events due to a drug intake and the frequency of single nucleotide polymorphisms (SNPs) before and after treatment in each group.The safety of administration of Benzimidazole will be evaluated primarily clinically. The safety will be evaluated within 24 hours and at any unscheduled visit or at week 3 and week 6 to record any symptoms that occur after the drug has been administered. | three to six weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Terminated |
NCT00319150 -
REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial
|
Phase 3 | |
Completed |
NCT00563875 -
Laboratory Aspirin Resistance in Diabetics and Non-Diabetics
|
N/A | |
Completed |
NCT00389129 -
Danish Aspirin Resistance Trial - Pilot Study
|
N/A | |
Terminated |
NCT00193947 -
An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination Antiretroviral Therapy
|
Phase 4 | |
Enrolling by invitation |
NCT06037564 -
B-free Multistage Trial
|
Phase 4 | |
Completed |
NCT01039480 -
Aspirin and Clopidogrel Resistance Study
|
N/A | |
Recruiting |
NCT05310370 -
HRD and Resistance to PAPPi in EOC Patients
|
||
Active, not recruiting |
NCT00457236 -
Effect of Clopidogrel Loading and Risk of PCI
|
N/A | |
Completed |
NCT02792816 -
Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar
|
N/A | |
Completed |
NCT01386476 -
(18F)FCWAY and the Blood-Brain Barrier
|
||
Recruiting |
NCT04990596 -
Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE)
|
||
Recruiting |
NCT03401957 -
The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment
|
N/A | |
Completed |
NCT04404582 -
Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection
|
||
Completed |
NCT02401204 -
Bacterial Transmission Dynamics Study
|
||
Completed |
NCT03114098 -
Pharmacogenetics Anomaly Research in Children and Adolescents With Pharmacological Resistance to Psychotropic Drugs
|
N/A | |
Recruiting |
NCT03361267 -
Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection
|
N/A | |
Completed |
NCT00302913 -
Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition
|
N/A | |
Completed |
NCT04833231 -
The Relationship Between Renal Functions and Multi Drug Resistant Organisms
|
||
Completed |
NCT00965042 -
Effect of Ceftobiprole on Human Intestinal Microflora
|
Phase 1 |